Search results for "randomized"

showing 10 items of 2323 documents

Automatic Segmentation of HEp-2 Cells Based on Active Contours Model

2018

In the past years, a great deal of effort was put into research regarding Indirect Immunofluorescence techniques with the aim of development of CAD systems. In this work a method for segmenting HEp-2 cells in IIF images is presented. Such task is one of the most challenging of automated IIF analysis, because the segmentation algorithm has to cope with a large heterogeneity of shapes and textures. In order to address this problem, numerous techniques and their combinations were evaluated, in a process aimed at maximizing the figure of merit. The proposed method, for a greater definition of cellular contours, uses the active contours in the last phase of the process. The initial conditions, c…

Active contour modelComputer sciencebusiness.industryHEp-2 cellComputingMethodologies_IMAGEPROCESSINGANDCOMPUTERVISIONProcess (computing)Pattern recognitionEllipseDice indexSettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)Hough transformlaw.inventionRandomized Hough transformHough transformlawPosition (vector)Convergence (routing)SegmentationArtificial intelligencebusinessActive contours modelCells segmentationIIF imagesProceedings of the 2018 3rd International Conference on Biomedical Imaging, Signal Processing
researchProduct

Mediterranean Diet Reduces the Adverse Effect of the TCF7L2-rs7903146 Polymorphism on Cardiovascular Risk Factors and Stroke Incidence

2013

OBJECTIVE Transcription factor 7-like 2 (TCF7L2) polymorphisms are strongly associated with type 2 diabetes, but controversially with plasma lipids and cardiovascular disease. Interactions of the Mediterranean diet (MedDiet) on these associations are unknown. We investigated whether the TCF7L2-rs7903146 (C>T) polymorphism associations with type 2 diabetes, glucose, lipids, and cardiovascular disease incidence were modulated by MedDiet. RESEARCH DESIGN AND METHODS A randomized trial (two MedDiet intervention groups and a control group) with 7,018 participants in the PREvención con DIetaMEDiterránea study was undertaken and major cardiovascular events assessed. Data were analyzed at b…

Malemedicine.medical_specialtyCardiovascular and Metabolic RiskMediterranean dietEndocrinology Diabetes and MetabolismPopulationType 2 diabetesDiet MediterraneanGastroenterologylaw.inventionRandomized controlled triallawRisk FactorsDiabetes mellitusInternal medicineInternal MedicinemedicineOdds RatioHumanseducationTriglyceridesOriginal ResearchAgedAdvanced and Specialized Nursingeducation.field_of_studyPolymorphism Geneticbusiness.industryIncidenceHazard ratioOdds ratioFastingMiddle Agedmedicine.diseaseStrokeEndocrinologyDiabetes Mellitus Type 2Cardiovascular DiseasesFemalebusinessTCF7L2Transcription Factor 7-Like 2 ProteinDiabetes Care
researchProduct

“Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colo…

2009

PURPOSE: Oxaliplatin combined with either fluorouracil/leucovorin (OXAFAFU) or capecitabine (OXXEL) has a demonstrated activity in metastatic colorectal cancer patients. We aimed at comparing these two regimens in terms of response rate (RR), safety, progression-free survival (PFS), and quality of life (QoL) of patients. METHODS: A total of 322 patients with metastatic colorectal cancer were randomized to receive biweekly: oxaliplatin 100 mg/m(2) i.v. on day 1, capecitabine 1,000 mg/m(2) orally twice daily from day 1 to day 11 (OXXEL); or oxaliplatin 85 mg/m(2) i.v. on day 1; 6S-leucovorin 250 mg/m(2) i.v. and fluorouracil 850 mg/m(2) i.v. on day 2 (OXAFAFU). RESULTS: Eleven complete and 42…

Settore MED/06 - Oncologia MedicacapecitabineoxaliplatinOXXEL regimenOXAFAFU regimencolorectal carcinomarandomized trial
researchProduct

2021

Introduction Since 2009, multiple randomized trials have shown faster and deeper responses in CML patients treated with new-generation TKI (NG-TKI) compared to those treated with imatinib (IM). Are the same results observed in the general population? Materials and methods Patients were identified from the three French hematological malignancies population-based registries. All CML patients (ICD-O-3: 9875/3) diagnosed between 2006 and 2016 and resided in registries areas were included. The TKI generation effect on achievement of MMR in first-line therapy was assessed through a multivariate competitive risk analysis. An alluvial plot described the pathways leading to death. Results In total, …

OncologyCancer Researchmedicine.medical_specialtymedicine.drug_classPopulationTyrosine-kinase inhibitorlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicineRadiology Nuclear Medicine and imagingeducationeducation.field_of_studybusiness.industryMyeloid leukemiaImatinibrespiratory tract diseases3. Good healthClinical trialOncology030220 oncology & carcinogenesisObservational studybusinessTyrosine kinase030215 immunologymedicine.drugCancer Medicine
researchProduct

Greedy randomized adaptive search procedure with exterior path relinking for differential dispersion minimization

2015

We propose several new hybrid heuristics for the differential dispersion problem, the best of which consists of a GRASP with sampled greedy construction with variable neighborhood search for local improvement. The heuristic maintains an elite set of high-quality solutions throughout the search. After a fixed number of GRASP iterations, exterior path relinking is applied between all pairs of elite set solutions and the best solution found is returned. Exterior path relinking, or path separation, a variant of the more common interior path relinking, is first applied in this paper. In interior path relinking, paths in the neighborhood solution space connecting good solutions are explored betwe…

Mathematical optimizationInformation Systems and ManagementHeuristic (computer science)GRASPComputer Science ApplicationsTheoretical Computer ScienceSet (abstract data type)Artificial IntelligenceControl and Systems EngineeringPath (graph theory)MinificationHeuristicsSoftwareVariable neighborhood searchGreedy randomized adaptive search procedureMathematicsInformation Sciences
researchProduct

A systematic review on regenerative alveolar graft materials in clinical trials

2021

Abstract Background Alveolar cleft grafting is a necessary procedure to restore bone defects. Randomized clinical trials (RCTs) are regarded as a golden standard for investigating the efficacy of treatments. Nevertheless, risk of bias (RoB) can still affect the validity of these trials. We aimed to conduct a systemic review of all control trials (CTs) using regenerative materials for alveolar cleft reconstructions to evaluate their RoB and perform a meta-analysis of new bone formation. Methods Cochrane Oral Health Group's Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (PubMed), EMBASE AND Google Scholar were searched up to October 2020. Thereafter, th…

medicine.medical_specialtyEvidence-based medicineMEDLINElaw.inventionIliumRandomized controlled triallawmedicineAdequacy of methodHumansTissue engineeringBone regenerationAutograftsIntention-to-treat analysisbusiness.industryEvidence-based medicineSDG 10 - Reduced InequalitiesRisk of biasJadad scaleSurgeryBone regenerationClinical trialCleft PalateMeta-analysisRegenerative medicine/dk/atira/pure/sustainabledevelopmentgoals/reduced_inequalitiesSurgeryCell transplantationbusinessAlveolar bone graftingJournal of Plastic, Reconstructive and Aesthetic Surgery
researchProduct

Pharmacokinetics of new oral anticoagulants: implications for use in routine care

2018

Introduction: Since 2008, new oral anticoagulants (NOACs) have been approved for the prevention of venous thromboembolism (VTE) in patients receiving hip or knee replacement surgery, prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF), treatment of deep vein thrombosis (DVT), and pulmonary embolism (PE). Premarketing randomized clinical trials (RCTs) of NOACs demonstrated their non-inferiority in terms of efficacy vs. warfarin (traditional oral anticoagulant–TOA), with lower risk of serious adverse drug reactions, especially cerebral hemorrhages. In clinical practice, pharmacokinetic aspects of NOACs have to be carefully taken into account to …

medicine.medical_treatmentnew oral anticoagulantsAdministration OralKnee replacement030204 cardiovascular system & hematologyToxicologyAdherence Bleeding Interactions New oral anticoagulants Over- and under-dosage Persistence Pharmacokinetics Real World Evidence0302 clinical medicineAtrial Fibrillationover- and underdosage030212 general & internal medicinepharmacokineticStrokeRoutine careRandomized Controlled Trials as Topicnew oral anticoagulantAtrial fibrillationpersistenceVenous ThromboembolismGeneral MedicinePulmonary embolismStrokepharmacokineticsHumanmusculoskeletal diseasesmedicine.medical_specialtyinteractionHemorrhageMedication Adherence03 medical and health sciencesPharmacokineticsmedicineHumansReal World EvidenceIn patientOver- and under-dosagecardiovascular diseasesreal-world evidenceIntensive care medicineAgedPharmacologybusiness.industryAnticoagulantAnticoagulantsinteractionsbleedingmedicine.diseaseAdherencePulmonary EmbolismbusinessVenous thromboembolismExpert Opinion on Drug Metabolism & Toxicology
researchProduct

Does chemotherapy prevent HCV-related hepatocellular carcinoma? Cons.

2010

The accuracy and the reliability of well-recognized clinical, virologic, histologic, and molecular risk factors for hepatocellular carcinoma (HCC) are still insufficient. Thus, accurate risk prediction of cancer development in individual patients with the aim of selecting high risk cohorts of patients for HCC chemoprevention programs remains an elusive goal. Future directions in chemoprevention of HCC will be in the development of molecular risk models and of new chemopreventive agents. Studies examining multiple genes and proteins (genomics and proteomics) in the same HCCs will be required to evaluate this possibility thoroughly. A strategy aiming at preventing chronic liver disease of any…

Oncologymedicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentInterferon alpha-2Chronic liver diseaseAntiviral AgentsChemopreventionlaw.inventionPolyethylene GlycolsRandomized controlled triallawInternal medicinemedicineHumansHCCChemotherapyHepatologybusiness.industryIncidence (epidemiology)Patient SelectionLiver NeoplasmsGastroenterologyInterferon-alphaHepatitis C Chronicmedicine.diseasedigestive system diseasesRecombinant ProteinsHepatocellular carcinomaImmunologyEtiologyCancer developmentbusinessDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Everolimus eluting bioresorbable vascular scaffolds in patients with acute coronary syndromes: Two‐year results from the German‐Austrian ABSORB regis…

2021

Abstract Objectives To identify potential differences in 2‐year outcome between patients who underwent coronary revascularization using bioresorbable vascular scafffolds (BVS) in stable coronary artery disease (CAD) and acute coronary syndromes (ACS). Background Data from randomized trials suggest a significantly higher event rate following coronary revascularization using everolimus‐eluting BVS as compared to new generation drug eluting stents. Whether particular patient subgroups are at increased risk for scaffold thrombosis and target lesion failure (TLF) has not clearly been demonstrated. Methods German‐Austrian ABSORB RegIstRy is a prospective all‐comer multi‐center observational study…

Target lesionmedicine.medical_specialtyTime FactorsMedizinCoronary Artery Disease030204 cardiovascular system & hematologyProsthesis Designlaw.inventionCoronary artery disease03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineRandomized controlled triallawInternal medicineAbsorbable ImplantsmedicineHumansRadiology Nuclear Medicine and imagingIn patientEverolimusProspective StudiesRegistries030212 general & internal medicineddc:610Acute Coronary SyndromeEverolimusbusiness.industryGeneral Medicinemedicine.diseaseThrombosisStenosisTreatment OutcomeAustriaCardiologyCardiology and Cardiovascular MedicinebusinessMacemedicine.drug
researchProduct

Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial.

2018

Current treatments for long-term prophylaxis in hereditary angioedema have limitations.To assess the efficacy of lanadelumab, a fully human monoclonal antibody that selectively inhibits active plasma kallikrein, in preventing hereditary angioedema attacks.Phase 3, randomized, double-blind, parallel-group, placebo-controlled trial conducted at 41 sites in Canada, Europe, Jordan, and the United States. Patients were randomized between March 3, 2016, and September 9, 2016; last day of follow-up was April 13, 2017. Randomization was 2:1 lanadelumab to placebo; patients assigned to lanadelumab were further randomized 1:1:1 to 1 of the 3 dose regimens. Patients 12 years or older with hereditary a…

AdultMalemedicine.medical_specialtyRandomizationAdolescentInjections SubcutaneousLanadelumabPlaceboAntibodies Monoclonal Humanizedlaw.invention03 medical and health sciencesYoung Adult0302 clinical medicineRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineHumans030212 general & internal medicineYoung adultAdverse effectChildPlasma KallikreinAgedHereditary Angioedema Types I and IIbusiness.industryAntibodies MonoclonalCorrectionGeneral MedicineMiddle Agedmedicine.diseaseClinical trial030228 respiratory systemHereditary angioedemaQuality of LifeFemalebusinessJAMA
researchProduct